Key Takeaways
- Osteoporosis is not an absolute contraindication for dental implants.
- Bisphosphonates (e.g. alendronate, zoledronate) increase the risk of jaw necrosis (MRONJ) — this must be discussed before treatment.
- The bone density in the jaw area is decisive, not systemic osteoporosis alone.
- With CBCT diagnostics and individual planning, implants are possible for many osteoporosis patients.
- Close collaboration between implantologist and treating internist/rheumatologist is essential.
Osteoporosis and dental implants: Is it possible?
Many patients with osteoporosis believe that dental implants are fundamentally out of the question for them. This assumption is wrong — but it is not entirely unfounded either. Osteoporosis affects bone structure throughout the body, and dental implants depend on stable bone anchorage. The decisive question, however, is not whether someone has osteoporosis, but how severely the jawbone is affected and which medications are being taken.
In this guide, we explain what osteoporosis does to the jawbone, which medications require special caution, and under what conditions implants are still possible.
What osteoporosis does to bone
Osteoporosis is a systemic disease in which bone density decreases and bone structure becomes more brittle. The spine, hip and wrist are primarily affected — but the jawbone can also be affected, although to a lesser extent than the large long bones.
For dental implants, the local bone density in the jaw area is decisive. This can be measured precisely with a CBCT (Cone Beam Computed Tomography). Many patients with systemic osteoporosis still have sufficient bone volume and density in the jaw area for successful implantation.
The real risk: Bisphosphonates and MRONJ
Important note on bisphosphonates
Bisphosphonates (e.g. alendronate/Fosamax, risedronate, zoledronate/Zometa) inhibit bone resorption — but also bone remodelling. This increases the risk of medication-related osteonecrosis of the jaw (MRONJ), especially after tooth extractions or implant placements. This risk must be carefully weighed before any treatment.
| Therapy type | Examples | MRONJ risk | Implant possible? |
|---|---|---|---|
| Oral bisphosphonates (low dose) | Alendronate, Risedronate | Low (< 0.1%) | Yes, with caution |
| Oral bisphosphonates (> 4 years) | Long-term alendronate | Moderate (0.1–1%) | Possible, after assessment |
| IV bisphosphonates (oncological) | Zoledronate, Pamidronate | High (1–10%) | Only in exceptional cases |
| Denosumab | Prolia, Xgeva | Similar to IV bisphosphonates | Only after consultation |
"Drug holiday": Bisphosphonate pause before the procedure
For oral bisphosphonates, a so-called "drug holiday" — a therapy pause of 3–6 months before the procedure — is frequently discussed. Whether this makes sense depends on the duration of use, individual osteoporosis risk, and the assessment of the treating internist.
Important: The decision about a drug holiday is not made by the dentist alone, but always in consultation with the prescribing physician. Independently interrupting bisphosphonate therapy can increase fracture risk.
When is an implant possible with osteoporosis?
How the diagnostic process works
- Complete medication history — all current and past bisphosphonate therapies must be documented, including duration and dosage.
- CBCT (Cone Beam CT) — 3D imaging of the jawbone to assess density, volume and quality.
- Consultation with the treating physician — internist, rheumatologist or oncologist must be involved in the planning.
- Laboratory values — for IV bisphosphonates, the CTX value (C-terminal telopeptide) can be helpful as a marker for bone remodelling activity.
- Individual risk assessment — only after complete diagnostics is a decision made on whether and how an implant is possible.
Questions to ask your doctor
- Which bisphosphonate am I taking exactly — and for how long?
- Is a drug holiday appropriate and safe in my case?
- What is my current bone density in the jaw area (CBCT)?
- Are there alternatives to implants that would be better suited for me?
- What follow-up care is particularly important for me after implantation?
Conclusion
Osteoporosis alone does not rule out a dental implant. The real risk lies in bisphosphonate therapy, not in the diagnosis itself. With careful CBCT diagnostics, close interdisciplinary coordination and individual risk assessment, implants are possible for many osteoporosis patients — and successful in the long term.
Institut für Implantologie und digitale Zahnmedizin Wien
Patientenaufklärung
Weitere Artikel
Thematisch verwandt
Hinweis: Diese Inhalte dienen ausschließlich der allgemeinen Information und ersetzen keine individuelle zahnärztliche Beratung. Das Institut für Implantologie und digitale Zahnmedizin Wien ist eine gemeinnützige, unabhängige Wissenschaftsplattform — kein Behandlungsbetrieb. Alle Angaben entsprechen dem aktuellen Stand der wissenschaftlichen Literatur; individuelle Behandlungsentscheidungen müssen stets mit einem approbierten Zahnarzt oder Facharzt getroffen werden.